ID 1469 -
Bifidobacterium animalis ssp. lactis Bb-12
PL: Bifidobacterium animalis ssp. lactis Bb-12
EN: Bifidobacterium animalis ssp. lactis Bb-12
Pdf: Bifidobacterium animalis ssp. lactis Bb-12
Oświadczenie (2)
- naturalne funkcji układu immunologicznego
1. Charakterystyka żywności / składnika
The food constituent that is the subject of the health claims is Bifidobacterium animalis ssp. lactis Bb-12.
The species and strain identity and characteristics of Bifidobacterium animalis ssp. lactis Bb-12 (previously known as Bifidobacterium bifidum Bb-12, and also as Bifidobacterium lactis Bb-12, but subjected to reclassification) (Masco et al., 2004) have been determined using different genotypic methods (Garrigues et al., 2005; Mayer et al., 2007; Ventura et al., 2001a; Yimin et al., 1999, unpublished). It is important to point out that it may not be possible to differentiate commercially available Bifidobacterium animalis ssp. lactis strains from each other on the basis of traditional genetic methods (e.g. Pulsed Field Gel Electrophoresis) (Engel et al., 2003; Gueimonde et al., 2004), and that it may be necessary to use multi-locus sequencing or genome-wide approaches. The genome of Bifidobacterium animalis ssp. lactis Bb-12, although sequenced (Yimin et al., 1999, unpublished), was not publicly available at the time of the evaluation.
The deposit of the strain in the German culture collection DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen) under number DSM 15954 was reported in the literature (Kajander et al., 2008). In addition, several authors consider the Bifidobacterium animalis ssp. lactis Bb-12 strain to be also equal to the strain DSMZ 10140 (Ventura et al., 2001b). This view is due to the fact that, although the strain owner did not deposit the strain under the Bifidobacterium animalis ssp. lactis Bb-12 name, strain DSMZ 10140 was isolated from a yoghurt containing Bifidobacterium animalis ssp. lactis Bb-12 which was deposited by Meile et al. (1997).
The Panel considers that the food constituent, Bifidobacterium animalis ssp. lactis Bb-12, which is the subject of the health claims, is sufficiently characterised.
2.4. Zmniejszenie dolegliwości związanych z chorobami zapalnymi jelit (ID 1469)
The claimed effect is “natural immune function”.
In the context of the proposed wording, the Panel assumes that the claimed effect refers to the reduction of symptoms of inflammatory bowel conditions.
The Panel notes that inflammatory bowel conditions are associated with Crohn's disease or ulcerative colitis, and that the target population for the claim is patients with Crohn's disease or ulcerative colitis.
The Panel considers that the claim does not comply with the criteria laid down in Regulation (EC) No 1924/2006.
Warunki i możliwe ograniczenia stosowania oświadczenia
Recommended target dose for a probiotic is 1.0 x 10 [9] colony forming units (cfu) per serving
5 x 10 [9] organisms per day